Immunogenicity and safety of GSK Biologicals' candidate tuberculosis (TB) vaccine (692342) when administered to healthy adults aged 21 to 40 years.
Phase of Trial: Phase II
Latest Information Update: 09 Sep 2009
At a glance
- Drugs GSK 692342 (Primary)
- Indications Tuberculosis
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 15 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Jul 2008 The expected completion date for this trial has been extended from Nov 2008 to Dec 2008 as reported by ClinicalTrials.gov.